Cell CycleMolecular BiologyPeer-reviewed journal article
Suppression of non-homologous end joining does not rescue DNA repair defects in Fanconi anemia patient cells
Supawat ThongthipiD, Brooke A. ContiiD, Francis P. LachiD, Agata SmogorzewskaiD
Abstract
Severe cellular sensitivity and aberrant chromosomal rearrangements in response to DNA interstrand crosslink (ICL) inducing agents are hallmarks of Fanconi anemia (FA) deficient cells. These phenotypes have previously been ascribed to inappropriate activity of non-homologous end joining (NHEJ) rather than a direct consequence of DNA ICL repair defects. Here we used chemical inhibitors, RNAi, and Clusterd Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas9 to inactivate various components of NHEJ in cells from FA patients. We show that suppression of DNA-PKcs, DNA Ligase IV and 53BP1 is not capable of rescuing ICL-induced proliferation defects and only 53BP1 knockout partially suppresses the chromosomal abnormalities of FA patient cells.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: cell-cell communication
- approach: experimental assay
- Citations
- 9
- FWCI
- 0.49
- Field percentile
- top 43%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Fanconi anemia core complex promotes CtIP-dependent end-resection to drive homologous recombination at DNA double-strand breaks
Bert van de Kooij, Fenna J. van der Wal, … Haico van Attikum·Nature CommunicationsPeer-reviewed·Aug 16, 2024
- HSF2BP Negatively Regulates Homologous Recombination in DNA Interstrand Crosslink Repair in Human Cells by Direct Interaction With BRCA2
Inger Brandsma, Koichi Sato, … Alex N. Zelensky·bioRxiv·Oct 16, 2018
- C1orf112 is a novel regulator of interstrand crosslink that decreases FIGNL1-RAD51 interaction
Edgar Pinedo Carpio, Julien Dessapt, … Alexandre Orthwein·bioRxiv·Oct 6, 2022
- Deficiencies in the Fanconi Anemia or the Homologous Recombination Pathway enhance the antitumor effects of the novel hypoxia-activated prodrug CP-506
Lesley Schuitmaker, Alexander Marie-Madeleine Adrianus van der Wiel, … Philippe Lambin·Molecular Therapy OncologyPeer-reviewed·Feb 24, 2026
- Fanconi anemia proteins are required to maintain nucleolar homeostasis.
A. Gueiderikh, G. Rouvet, … F. Rosselli·bioRxiv·Jan 2, 2019
- Generating new FANCA-deficient HNSCC cell lines by genomic editing recapitulate the cellular phenotypes of Fanconi anemia
R. Errazquin, E. Sieiro, … R. Garcia-Escudero·bioRxiv·Oct 3, 2020